Effects of peripheral inflammation on the blood-spinal cord barrier
© Xanthos et al.; licensee BioMed Central Ltd. 2012
Received: 6 March 2012
Accepted: 18 June 2012
Published: 18 June 2012
Changes in the blood-central nervous system barriers occur under pathological conditions including inflammation and contribute to central manifestations of various diseases. After short-lasting peripheral and neurogenic inflammation, the evidence is mixed whether there are consistent blood-spinal cord changes. In the current study, we examine changes in the blood-spinal cord barrier after intraplantar capsaicin and λ-carrageenan using several methods: changes in occludin protein, immunoglobulin G accumulation, and fluorescent dye penetration. We also examine potential sex differences in male and female adult rats.
After peripheral carrageenan inflammation, but not capsaicin inflammation, immunohistochemistry shows occludin protein in lumbar spinal cord to be significantly altered at 72 hours post-injection. In addition, there is also significant immunoglobulin G detected in lumbar and thoracic spinal cord at this timepoint in both male and female rats. However, acute administration of sodium fluorescein or Evans Blue dyes is not detected in the parenchyma at this timepoint.
Our results show that carrageenan inflammation induces changes in tight junction protein and immunoglobulin G accumulation, but these may not be indicative of a blood-spinal cord barrier breakdown. These changes appear transiently after peak nociception and may be indicative of reversible pathology that resolves together with inflammation.
KeywordsBlood-spinal cord barrier Capsaicin Carrageenan Spinal cord Occludin Lumbar Immunoglobulin Female Inflammation
The central nervous system (CNS) is separated and protected from the peripheral environment and blood by the blood–brain/spinal cord barriers (BBB/BSCB), homeostatic control mechanisms of specialized microvasculature which include astrocyte endfeet, endothelial cells, tight junctions, and adherens [1, 2]. Various neuroinflammatory diseases such as multiple sclerosis, meningitis, Alzheimer’s disease, and ischemia can result in “breakdown” of the BBB . Pathological conditions that are shown to disrupt the BSCB include traumatic spinal cord injury , CNS degenerative disorder , CNS inflammation , or peripheral nerve injury . Breakdown of the blood-CNS barriers will result in leakage of bioactive substances, neurotransmitters, and immune cells from the blood that can contribute to disease progression and impact drug treatments.
In recent years, the complexity of blood-CNS barriers has been shown to involve multiple physical barriers and specific transport components which could potentially be variably modulated in pathological conditions . Acute stimuli or pathology such as seizures , radiation exposure , acute stress , drugs , or hyperthermia , can transiently increase the permeability of the BBB. Early and selective changes prior to disease onset with specific mechanisms such as rapid activation of immune cells, for example, mast cells, have also been identified in various diseases including contusive brain injury , ischemic brain injury , and multiple sclerosis .
Peripheral inflammatory stimuli have been shown to induce “breakdown” of the BSCB in some studies, however other results have been conflicting. In one study, carrageenan inflammation induced increased Evans Blue dye extravasation at 48 hours post-carrageenan , although this was not systematically studied or replicated. In other studies, complete Freund’s adjuvant (CFA) or carrageenan inflammation are apparently not reported to induce Evans Blue dye leakage at 24 hours post-administration  or at 72 hours post-CFA administration . However, morphine penetration is apparently increased specifically in the spinal cord after CFA or carrageenan at 24 hours post-administration . It has also been shown that electrical nerve stimulation at C-fiber intensity or direct application of capsaicin onto the nerve can cause Evans Blue dye leakage in the entire spinal cord at 24 hours post-stimulation . However, in another study, peripherally-injected formalin induces BSCB changes as evidenced by albumin extravasation beginning at 4–6 days, but peaking at 7–10 days post-administration  suggesting that this may not be directly related to nociceptive behaviors or hyperalgesia maintenance. It may be speculated that changes in the BSCB particularly in peripheral inflammation may be related to the particular timepoints, particular mechanisms or sensitivity assessed by the various methods used, and characteristics of the animal model. In addition, there may be sex, or strain differences in BSCB disruption as seen in some studies in the brain [22–24] which may affect results in animal models of inflammatory pain. There has been no study using multiple methods at different timepoints to assess changes in the BSCB after peripheral inflammation.
In the current study, we measured changes in the BSCB after intraplantar capsaicin and carrageenan in both male and female rats using three different approaches: changes in morphology of the tight junction protein occludin, endogenous immunoglobulin (IgG) parenchymal permeation, and small size exogenously administered sodium fluorescein (NaFl) permeation. We used multiple early and late timepoints after capsaicin and carrageenan in the hopes of also determining whether changes may be identified as initiating or maintaining the apparent peripheral inflammation and expected nociception. Contrary to expected, we found transient changes using some methods to assess the blood-spinal cord barrier that occurred at a later timepoint not associated with peak nociception. Specifically, our results show changes in spinal occludin protein morphology and presence of IgG in endothelial cells and nervous tissue at 72 hours post-carrageenan in male and female rats, but no major lumbar spinal cord structural changes or increased penetration of exogenously injected small-molecule fluorescent dye.
Effect of capsaicin and carrageenan on nociception and spinal tight junction protein occludin
Also as expected, intraplantar carrageenan induced significant thermal hyperalgesia (Figure 1C and Figure 1D), as measured by the Hargreaves plantar test and significant mechanical hyperalgesia (Figure 1E and Figure 1F), as measured using the calibrated forceps test in both male and female rats. For thermal testing, two-way repeated measures ANOVA revealed a highly significant effect of group in male (F3, 80 = 40.2; P < 0.001) and female rats (F4, 80 = 36.2; P < 0.001). Post hoc analysis showed significant differences at all time points tested after carrageenan in the ipsilateral hindpaw as compared to vehicle in male rats (P < 0.05 and P < 0.001 at 3 hours and 24 hours) and female rats (P < 0.05 and P < 0.001 at 3 hours, 24 hours, and 48 hours). For mechanical testing, two-way repeated measures ANOVA also revealed a highly significant effect of group in male (F3, 80 = 32.5; P < 0.001) and female rats (F3, 80 = 38.7; P < 0.001). Posthoc analysis showed significant differences after carrageenan as compared to vehicle at all time points tested in the ipsilateral hindpaw in male rats (P < 0.05 and P < 0.001 at 3 hours, 24 hours, 48 hours, and 72 hours) and female rats (P < 0.05 and P < 0.001 at 3 hours, 24 hours, and 48 hours).
Intraplantar carrageenan induces IgG extravasation at 72 hours post-carrageenan
As with the occludin study, IgG appeared to show effects that were not restricted to the ipsilateral dorsal horn. Hence, we also searched for IgG accumulation in the thoracic region and found that it was also present at the 72 hour post-carrageenan timepoint in several animals which also had lumbar IgG staining. One-way ANOVA revealed a non-significant trend group effect (F6, 28 = 2.3l; P > 0.05), although the post-hoc test revealed significantly increased fluorescence intensity at 72 hour post-carrageenan as compared to vehicle (P < 0.05) (Figure 5C). This suggested a spread of this effect beyond the lumbar spinal cord, but again not seen with systemically-administered carrageenan.
In the 72 hour post-carrageenan groups, IgG staining appeared to be mostly restricted to endothelial cells, as demonstrated by VWF staining. However, in some cases, it was clearly present outside the endothelial cells suggesting some extravasation does occur (Figure 5A and Figure 5B). We could not systematically detect IgG inside neurons as we saw in the EAE model (data not shown), suggesting that extravasation was mild. In order to search for a common mechanism for BSCB breakdown, we also performed triple staining with VWF, IgG, and occludin in the 72 hour treated carrageenan male and female rats (Figure 5G). By selecting vessels that showed IgG extravasation, we blindly assessed the status of occludin protein (as above) in 206 vessels from 3 male and 3 female rats. While we expected the number of disturbed occludin protein to be particularly high in these vessels, it was surprisingly within the range previously measured with double staining. This suggested to us that occludin disturbance and IgG accumulation are distinct mechanisms which occur independently.
Histological assessment, Evans blue, and sodium fluorescein dye leakage
We then used other methods to assess the BSCB by searching for spinal cord structural changes by histological staining  and measuring the extravasation of intravenously administered small molecule fluorescent dyes such as Evans Blue and sodium fluorescein (NaFl) [19, 27].
In separate rats, NaFl (molecular weight of 376 Daltons) or Evans Blue (molecular weight of 960 Daltons) dyes were administered intravenously and allowed to circulate for at least 30 minutes under inhalable anaesthesia. Leakage into the parenchyma of lumbar, thoracic, cervical, midbrain, and cerebral cortex was then quantified in vehicle-injected, 72 hour post-carrageenan injected male and female rats, and intrathecal LPS controls. A clear yellow staining for NaFl or blue staining for Evans Blue was visually detected in the spinal cord segments upon removal in LPS injected rats. For Evans Blue, two-way ANOVA revealed a significant effect of group (F4, 70 = 5.63; P < 0.05), and region (F4, 70 = 14.1; P < 0.05). Significant differences were detected by posthoc between LPS and vehicle groups in the lumbar (P < 0.05), thoracic (P < 0.001), and cervical (P < 0.05) regions, but not between vehicle and carrageenan treatment group. A similar pattern was seen in separate experiments using NaFl dye injection. Two-way ANOVA of fluorescence values revealed a highly significant effect of group (F4, 65 = 28.28; P < 0.001), region (F4, 65 = 7.57; P > 0.05) and interaction (F16, 65 = 2.38; P > 0.05). Significant differences detected by posthoc from the LPS and vehicle rats were seen in the lumbar and thoracic regions (P < 0.001), also significant in the cervical region (P < 0.05), but not in brain regions (P > 0.05). There were no significant differences at the 72 hour timepoints in neither the male nor the female carrageenan rats (Figure 5). Similar results had also been obtained with in vivo imaging using rhodamine-based dyes (data not shown). These results suggested to us that the above methods to assess the BSCB involve different mechanisms than tight junction protein or endogenous IgG assessment and emphasizes the importance for the use of multiple methods to assess the BSCB after transient pathology. In summary, changes in spinal occludin and presence of endothelial and/or parenchymal IgG can be detected transiently at 72 hours post-carrageenan, but not fluorescent dye extravasation or lumbar spinal cord structural changes which may all be necessary to conclude a “breakdown” in the BSCB.
Altered blood-CNS barriers can involve transient and specific changes with a complex functional effect on permeability of endogenous substances, immune cells, or drug treatments. Alterations in specific mechanisms such as changes in transporter proteins, tight junctions, and immune cell penetration can occur quickly in various conditions such as stress or xenobiotic exposure [28–30]. Transient changes are less studied than those that cause a clear “breakdown” of the BSCB in chronic diseases, those that can impact the BSCB for weeks and months such as spinal cord trauma, CNS inflammation, or peripheral nerve injuries. In the current study, we studied capsaicin neurogenic inflammation which induced mechanical hyperalgesia that peaked at about 2–3 hours and lasts for at least 24 hours, and carrageenan inflammation which induced mechanical and heat hyperalgesia that peaked at about 3–24 hours and lasts for at least 72 hours. Decreased intact occludin morphology was found in male rats and IgG extravasation in lumbar and thoracic spinal cord in both male and female rats. Interestingly, these effects were only detected at 72 hours post-carrageenan, a late timepoint, one which is beyond the peak hyperalgesia in this model and in which the inflammation is subsiding. As we did not find increased extravasation of exogenously administered small size fluorescent dye either Evans Blue or sodium fluorescein at ~30 minutes post-administration in these animals, this suggests that there is no generalized “breakdown” of the BSCB.
In the first experiments, we found that intact occludin on endothelial cells was disrupted after intraplantar carrageenan administration at 72 hours post-administration in male rats, but not after capsaicin administration or subcutaneous carrageenan. Various studies have shown that the presence of occludin protein determines tight junction permeability [31, 32] and hence its disruption will influence the BSCB. Several chronic disease models show decreases in total spinal occludin protein such as EAE , diabetes , and nerve injury . Intraplantar carrageenan has been shown to induce a biphasic effect on radioactive glucose permeability in the brain which parallels decreases in occludin from isolated microvessels with a peak at 1–6 hours post carrageenan and also at 48 hours post-carrageenan . Interestingly, while we found decreased intact occludin morphology after carrageenan, we did not find a corresponding decrease in occludin protein and we also did not find evidence for a biphasic effect. It is possible that we were unable to detect changes in specific isoforms. Occludin has different phosphorylation sites and the highly phosphorylated occludin form has been suggested to be the functional form of the protein [36, 37]. Peripheral carrageenan has been shown to induce changes in the relative amount of oligomeric, dimeric, and monomeric isoforms of occludin associated with brain endothelial cells . However, it is also interesting to note that accumulating evidence suggests that there may be various differences between the BBB and BSCB such as, for example, differences in transporter and occludin expression  or regional differences in penetration of radioactive tracers and cytokines [39, 40]. It would be interesting for future studies to simultaneously compare the timecourse of changes in both spinal and brain regions. Nevertheless, after EAE inflammation, dephosphorylation of spinal occludin has been shown to coincide with disruption in occludin morphology . As we did detect decreased total occludin levels in the spinal inflammation positive controls, but not carrageenan, this may suggest that morphological changes may be more sensitive indicators of early BSCB disruption.
The timing of occludin morphology disturbance 72 hours after carrageenan was paralleled by the presence of IgG in endothelial cells and parenchyma. IgG is a large ~150 kDa molecule that under normal conditions does not cross the BSCB. Its presence in the cerebrospinal fluid has been labeled as a marker of disease clinically . Various disease models such as apolipoprotein-E knockout mice , rat spinal cord injury , and partial sciatic nerve ligation  show IgG accumulation in the spinal cord. In the superoxide dismutase-1 mutant rat model of amyotrophic lateral sclerosis, IgG is also reported in the lumbar spinal cord and cortex, although interestingly at the pre-symptomatic stage prior to changes in occludin and increased penetration of Evans Blue dye . We did detect IgG in the nervous tissue, although a large part of the IgG appeared to compartmentalize or stay within the endothelial cells in the carrageenan treated animals. Given that our vehicle-treated animals did not show IgG and the effect occurred only at 72 hours post-carrageenan, we do not believe that this is an artifact of perfusion or due to vascular abnormalities. It would be interesting to speculate that this IgG accumulation in endothelial cells may signal an early change of the BSCB which does not progress to a more generalized “breakdown”. Interestingly, IgG was further detected in the thoracic spinal cord indicating a widespread effect. Evans Blue extravasation after electrical C-fiber stimulation of the sciatic nerve or after peripheral nerve injury is also reported to occur in the thoracic spinal cord  and our changes in occludin protein were not restricted to the ipsilateral dorsal horn. It is also known that spread of BSCB changes can occur in a delayed manner after spinal cord injury  and that hyperalgesia can spread beyond the injury site in various animal models. Although we did not detect significant contralateral nociception in our animal model, several potential mechanisms for spreading and secondary hyperalgesia could also be involved here to explain why changes would not be restricted to the ipsilateral lumbar dorsal horn. These include activation of the astrocytic network, disinhibition, infiltration of immune cells, volume transmission in the CSF, heterosynaptic long-term potentiation, involvement of commissural interneurons, and of descending facilitation . It can also be speculated that there may be a delayed release of a humoral mediator. However, it should be emphasized that carrageenan administered subcutaneously did not induce any IgG accumulation at 72 hours post-administration. Hence, it is likely that the peripheral ongoing nature of the inflammation in the hindpaw tissue is responsible for the late-occurring IgG extravasation which is clearly different from a systemic or CNS inflammation. Nevertheless, it is intriguing to consider how other peripherally administered agents beyond carrageenan may also have subtle and spreading CNS effects beyond the usual endpoints measured related to hindpaw nociception and the lumbar dorsal horn.
Testing the permeability of the BSCB after injection of the small molecular weight NaFl did not reveal an increased permeability at the 72 hour post-carrageenan timepoint in neither male nor female rats. Most studies on barriers have traditionally used Evans Blue which has a higher molecular weight than NaFl. Leakage has been shown to occur as early as 3 days after nerve injury  or 24 hours after capsaicin or sciatic nerve stimulation . Interestingly, carrageenan was reported to induce spinal Evans Blue leakage in one study , although neither brain nor spinal cord leakage in another . In vitro, endothelial cells treated with adrenomedullin show increased permeability to NaFl, but not Evans Blue . Also in vivo after nerve injury, NaFl shows greater differences in leakage as compared to Evans Blue . Hence, sensitivity is likely higher using the NaFl dye. However, it is also known that NaFl binds to transport proteins such as organic anion transporter [48, 49]. In streptozotocin-treated diabetic rats, there is increased BBB permeability as evidenced by increased penetration of radioactive sucrose and decreased tight junction protein , but actually decreased permeability to fluorescein explained by upregulation of transporters in this model . Increased morphine penetration is also reported in peripheral inflammation which does not coincide with increased Evan Blue dye penetration . It is interesting to speculate whether the reported increased systemic analgesic sensitivity after inflammation for opioids  or other drugs  can be due only to changes in the BSCB as detected in our study.
In addition, we performed hematoxylin/eosin and Nissl staining in lumbar spinal cord in 72 hour animals. Previous reports have indicated structural alterations in the spinal cord after nerve injury  and in the brain with acute stimuli such as hyperthermia and methamphetamine administration [54, 55]. We did not detect such extensive changes as in the literature in the 72 hour post-carrageenan group, and although we did find occasional instances of perivascular edema, this was not systematically quantified and electron microscopy was not used in our study. Future comprehensive studies to quantify the presence of minor structural abnormalities may be interesting to establish the sensitivity of this method for detecting more subtle changes in the BSCB.
We hypothesized that we could detect sex differences in the BSCB. As within the pain literature [56, 57], there are reports of sex differences in the BBB which prompted us to examine this topic for the first time in this context. Effects of sodium selenite and antioxidants are reportedly greater in males than in females which have greater alterations of BBB permeability in some models of epilepsy [58, 59]. However, other studies show greater permeability in female mice to selenium as compared to male mice during systemic inflammation . Radio frequency radiation also appears to show BBB disruption in male rats but not female rats . Interestingly, multiple studies that have found changes in the BBB after peripheral carrageenan were performed only in female rats [62, 63]. In our study, we detected a significant difference in male rats in the occludin study, however both for male and females in the IgG study. This appeared to us to be due to greater baseline variability in females. It is possible that particular estrous cycle stages may influence occludin morphology. The effect of lifetime estrogen changes and exogenous estrogen administration has been speculated to influence BBB penetration, loss of occludin protein, and appearance of IgG [23, 64]. It would be interesting for future studies to systematically examine whether particular estrous cycle phases may alter susceptibility to changes in BSCB.
The timecourse of the changes seen in occludin morphology and IgG extravasation in our study does not provide a direct correlation between the initiation or peak nociception and changes in the BSCB, since carrageenan hyperalgesia peaks within a few hours. This is intriguing given that direct electrical stimulation of nociceptive C-fibres of the sciatic nerve causes a widespread opening of the BSCB prevented by locally applied lidocaine  or the prevention of BBB permeability and tight junction proteins alteration by bupivacaine nerve block ). Animal models of peripheral inflammatory pain show specific changes in the BBB which can occur shortly after the stimulus when nociception is present. Injection of 5% formalin, 3% carrageenan, or CFA induce changes in brain tight junction proteins and increased brain permeability to radioactive sucrose at 1 hour, 3 hours, and 48 hours [35, 65, 66]. Whereas anti-inflammatory treatments such as rapamycin or diclofenac reduce blood-CNS barrier breakdown together with hyperalgesia [62, 67], no studies establish BSCB alterations as necessary and sufficient for nociception. Changes in the BSCB may also be secondary effects nonspecific to nociception and as other indicators of central inflammation may be dissociable from measurable nociceptive behaviors [68, 69]. In the current study, the doses of capsaicin and carrageenan used were on the high range as compared to the literature making it unlikely that lower or more commonly used doses of capsaicin or carrageenan would have elicited more extensive changes on the BSCB. If due to the nociceptive barrage, early effects should be expected in the first synapse of spinal cord, but we could not detect this with capsaicin or early after carrageenan. It can also be speculated that changes detected at 3 days post-carrageenan are not related to peak nociception in peripheral inflammatory pain, but perhaps to compensatory “healing” mechanisms. Our study used multiple methods to assess whether there is “breakdown” of the barrier and suggests that each method may detect particular mechanisms involved in changes in the BSCB.
In summary, we have found evidence of changes in spinal occludin protein and appearance of IgG around endothelial cells occurring with a delayed onset after peripheral inflammation and nociception. These changes are transient and are not restricted to spinal cord areas of nociceptive input. We conclude that peripheral inflammation induces transient changes in the spinal cord indicative of an altered BSCB but these do not appear linked directly to nociceptor activation.
Male and female Sprague–Dawley rats (175–250 grams) were used in all experiments and obtained from the Medical University of Vienna local breeding facility (Himberg, Austria), except in EAE complex inflammation where Lewis rats were used (obtained from Charles River, Germany). Rats were housed 4–6 per cage in a unisex manner under 12/12 light dark cycle at temperatures between 20-25°C and humidity between 40-60%. Food and water was provided ad libitum. Animals were handled at least twice prior to use and care was taken to minimize stress during all experimental procedures. All experimental procedures were approved by the ethics committee of the Medical University of Vienna (MUW) and the Austrian Ministry for Science and Research (BMWF), and conform to the animal experimentation standards of the International Association for the Study of Pain (IASP).
Capsaicin (1% sonicated in mild heat in 80% 0.9% NaCl, 10% pure ethanol, 10% Tween-80; Sigma) was injected into the hindpaw at a volume of 25 μl under inhalable anaesthesia with oxygen, nitrous oxide (N2O) and isoflurane. λ-carrageenan (3% mixed vigorously in NaCl) was injected into the hindpaw at a volume of 100 μl also under gas anaesthesia. In some groups, carrageenan was administered in the nape of neck subcutaneously at the same volume and dose. As positive controls for spinal inflammation, LPS was injected intrathecally as per  with a first injection of 2 μg/30 μl followed by a second injection of 20 μg/30 μl 24 hours later. The animal was sacrificed 3 hours after the second injection. For the EAE positive control, male and female Lewis rats were used as previously described  and sacrificed 7–10 days after induction of complex inflammation.
In the first group of experiments, male and female rats (n = 6 per group) were injected intraplantar with 1% capsaicin or vehicle, and nociception was measured at 1, 2, 3, 4, and 24 hours post injection. Mechanical thresholds were measured using a set of calibrated Von Frey filaments (Stoelting Europe, Dublin, Ireland) between 0.4 grams and 15 grams with animals standing on a wire mesh inside clear Plexiglas boxes. The caudal region behind the ipsilateral footpad was stimulated three times using a three-second stimulation. A positive response was counted when a clear hindpaw withdrawal occurred, not due to movement of the animal. Ascending hairs were presented in a systematic manner starting with the 2 gram hair. After the first response was obtained, four additional hairs were presented using the up-down method based on . The 50% paw withdrawal threshold was then interpolated using the formula: 50% g threshold = (10[xf +kδ])/10,000, where x f = value (in log units) of the final von Frey hair used; k = tabular value (see  for pattern of positive/negative responses; and δ = mean difference (in log units) between stimuli in each pattern used and stimulation in adjacent areas in this same region. The contralateral paw was always tested first followed by the ipsilateral paw.
In the second group of experiments, male and female rats (n = 6 per group) were injected intraplantar with 3% carrageenan or vehicle, and nociception was measured at 3, 24, 48, and 72 hours post-injection. Mechanical thresholds were measured using a calibrated forceps (Bioseb, Vitrolles, France). Habituated animals were briefly and lightly restrained in a soft towel inhibiting visual stimulation. The hindpaw was progressively squeezed at a rate of approximately 100 g per second. The mechanical threshold was electronically obtained when the animal clearly withdraw its hindpaw and/or vocalized. Three readings per hindpaw for the baseline and two readings per hindpaw for the timepoints post-injection were measured with a 10-minute inter-testing interval. Thermal latencies were measured using the plantar Hargreaves Apparatus (Stoelting Europe, Dublin, Ireland). The animals were placed on a heated glass floor (30°C) and the time latency to hindpaw withdrawal (not due to movement) was measured with application of the light source on the region caudal to the foot pads. The radiant heat intensity was set to an arbitrary value that elicited a baseline withdrawal latency of about 10–12 seconds at the beginning of the experiment. Three baseline readings were performed and averaged for analysis. Thereafter, two readings per hindpaw were averaged for the timepoints post-injection with a 10 minute inter-testing interval. The contralateral paw was always tested first followed by the ipsilateral paw.
Occludin and VWF staining and quantification
For capsaicin experiments, male (n = 4-6 per group) and female (n = 4-5) animals were sacrificed at 10 minutes, 3 hours, 24 hours and 72 hours (only in males) after 1% capsaicin or vehicle injection. For λ-carrageenan experiments, male (n = 5-8 per group) and female (n = 5-6 per group) animals were sacrificed at 3 hours, 24 hours, 72 hours, and 120 hours (only in males) after λ-carrageenan or vehicle injection. To collect the spinal cord, animals were deeply anaesthetized using ether and decapitated. The spinal cord was removed immediately using pressure expulsion by injecting cold PBS in the spinal column at the sacral level using a 18-gauge needle. Thereafter, the lumbar region was carefully dissected, snap-frozen in isopentane, and stored at −80°C. 14-μm-thick transverse slices of the L5 lumbar region were sectioned at −20°C and placed on slides. After drying, slides were fixed in 100% ethanol for 30 minutes at 4°C and then acetone for 3 minutes at −20°C. Thereafter, slides were washed once with PBS and blocked with 5% normal donkey serum (NDS) at room temperature for 30 minutes. Sections were then incubated with the primary antisera mouse anti-occludin (1:1000 dilution in 5% NDS; Invitrogen) and rabbit anti-VWF (1:4000 dilution in 5% NDS; Sigma-Aldrich) for 1 hour at room temperature. Afterwards, the sections were washed with PBS and incubated with the secondary antibodies goat anti-mouse Cy2 (1:200 in PBS; Jackson Immunoresearch) and donkey anti-rabbit Cy3 (1:400 in PBS; Jackson Immunoresearch) for 1 hour at room temperature. After final washing with PBS, slides were coverslipped with Aquatex® (Merck Millipore, Darmstadt, Germany).
To investigate occludin expression, the sections were analyzed using a fluorescence microscope (Olympus BX51) and pictures were acquired using a colour fluorescence camera (Olympus DP50). Discrete occludin was counted in every spinal cord quadrant (ipsilateral ventral, ipsilateral dorsal, contralateral ventral, contralateral dorsal) in comparison to the VWF staining, and the expression within each vessel was manually classified as “intact” (clear lines of occludin), “partial” (less than 80% occludin per vessel), “foggy” (diffuse distribution of occludin) and “lacking” (no occludin) by an experimenter blinded to the sample identity. Between ~60 and 100 vessels per quadrant were randomly counted with this method.
Male (n = 4-5 per group) and female (n = 4-6 per group) animals were used that had undergone the following treatments: vehicle, 3 hours post-carrageenan, 24 hours post-carrageenan, 72 hours post-carrageenan, 120 hours post-carrageenan, subcutaneous carrageenan (72 hours post), and 24 hours post-capsaicin. Rats were deeply anaesthetized using ether and perfused intracardially at a rate of ~10 ml/min using a peristaltic pump with 150 ml oxygenated PBS which was warmed to 37°C. The spinal cord was then immediately removed by pressure expulsion with cold saline and snap-frozen in isopentane and stored at −80°C. 14-μm-thick transverse slices of the L5 lumbar region and T3 thoracic regions were sectioned using a cryotome at −20°C. After drying for 1 hour, the slides were fixed in 100% ethanol for 1 hour at 4°C and for 3 minutes in acetone at −20°C. After washing with PBS, they were blocked with 5% NDS in PBS with 0.1% TritonX-100 for 30 minutes. Sections were then incubated in rabbit anti-VWF (1:4000) and donkey anti-Rat IgG Cy3 (1:600; Chemicon) over night at 4°C. The sections were then washed with PBS and incubated for 1 hour at room temperature with the secondary antibodies: donkey anti-rabbit Cy2 (1:200 in PBS) and again donkey anti-rat IgG Cy3 (1:600 in PBS). Sections were washed again with PBS and the slides were coverslipped with mounting medium.
To analyze the IgG staining intensity as a marker for the BSCB integrity, we used a semi-quantitative method. Pictures of the ipsilateral dorsal region of the slides were taken at 400X magnification with a fluorescence microscope and colour camera (Olympus BX51 and DP50) using a consistent exposure time. Three non-consecutive sections from each of the different groups were blocked and randomized per experimental session and the experimenter taking the photographs was blind to the experimental treatment. For analysis, a consistent colour threshold was set to subtract the background and the pictures were binarized using CellD 3.3 (Olympus Soft Imaging Solutions). The integrated density (area X mean grey value) of the whole images was measured using ImageJ software (National Institute of Health) and averaged per group.
Triple staining-occludin, IgG, and VWF
A similar procedure as the IgG/VWF was used. The antibodies used in this case were primary guinea pig anti-Occludin (1:10; Hycult Biotech), rabbit anti-VWF (1:4000) and donkey anti-Rat IgG Cy3 (1:600) overnight at 4°C. All antibodies were diluted with 0.1% PBST + 5% NDS. To investigate a direct correlation between IgG extravasation and occludin distribution, lumbar sections from male and female 72 hours post-carrageenan groups (n = 6) were used and occludin protein in those endothelial cells co-staining with IgG from the ipsilateral dorsal regions was classified as above into intact, partial, foggy, or no staining. 15–40 vessels per animal were analyzed. Representative pictures of the triple staining were made with the monochrome fluorescence camera (Olympus XM10).
Western blot for occludin
Male and female animals (n = 4-8 per group) treated with either vehicle, 72 hours post-carrageenan, or 72 hours after subcutaneous carrageenan were used in these experiments. Male intrathecally injected LPS (n = 4 per group), naive and EAE animals were used as control groups for the assay. Rats were decapitated and the spinal cord was removed by cold PBS pressure expulsion. The lumbar spinal cord (L4-L6) was snap frozen at −80°C in isopentane and stored at the same temperature until further processing. Tissue samples were homogenized in Lämmli-buffer including protease inhibitors (Complete Mini, EDTA-free, Roche), heated to 70°C for 10 minutes, vortexed, heated to 95°C for 5 minutes and centrifuged for 10 minutes at 4°C and 14.000 g. Supernatants were then collected and equal amounts of protein were size fractioned by SDS-PAGE (8% gel) using the Mini-Protean 3 Cell- system (Bio-Rad) and transferred onto a nitrocellulose membrane (Protran, Whatman). The membrane was placed in blocking buffer, consisting of dry milk powder and Tween-80 (Sigma) in phosphate buffered saline for 1 hour and then incubated over night at 4°C with primary polyclonal antibody to Occludin (rabbit anti-occludin 1:700, Invitrogen). The expression of ß-Actin (monoclonal anti-ß-actin 1:700, Sigma) was used as an internal loading control. All antibodies were diluted with blocking buffer. The blots were washed three times for 15 minutes each and then incubated with peroxidase-conjugated anti-rabbit IgG and peroxidase-conjugated anti-mouse IgG, respectively, for 2 hours at room temperature. Secondary antibodies were purchased from Jackson Immuno Research. After washing the blots three times for 15 minutes each, the bands were visualized by the Immobilon Western Chemiluminescent HRP Substrate (Millipore) and detected by the Fluor-S MultiImager (Bio-Rad). Densitometric quantification of the bands was performed with the Quantity One software (Bio-Rad). Background was subtracted for each lane, and ratio between β-actin band density and pre-determined areas of low and high molecular occludin band density was determined by a blinded experimenter.
Rats were deeply anaesthetized using ether and perfused intracardially first with 25 ml saline followed by 175 ml 4% PFA at a rate of ~10 ml/min using a peristaltic pump. The following groups (n = 3-4 per group) were collected: vehicle male, vehicle female, 72 hours post-carrageenan male, 72 hours post-carrageenan female, intrathecal LPS. The entire spinal cord column was dissected and post-fixed in 4% PFA overnight. The spinal cord was then removed by laminectomy and placed in 20% sucrose overnight, and 30% sucrose for 2 additional days, prior to being snap-frozen in isopentane and stored in −80°C until further processing. Frozen 8–10 μm sections from the lumbar spinal cord were then cut with a cryostat. Hematoxylin/Eosin and Nissl stainings were performed as per a standardized protocol on multiple sections per animal. Slides were coverslipped using Eukitt® (Sigma-Aldrich, Vienna, Austria).
Evans blue dye and sodium fluorescein penetration assay
Male and female animals (n = 3-6 per group) from the following groups were used in this assay: vehicle, intraplantar carrageenan 72 hours post administration, subcutaneous carrageenan 72 hours post administration, and intrathecal LPS. Sodium fluorescein (10% in 2 ml/kg) (Sigma) or Evans Blue dye (3% in 4 ml/kg) (Sigma) was infused into a cannulated femoral vein and allowed to circulate for 30–40 minutes while the animal was kept under isoflurane/N2O anaesthesia. Animals were then immediately intracardially perfused with ~150 ml saline at a rate of ~10 ml/min using a peristaltic pump. Spinal lumbar, spinal thoracic, spinal cervical, midbrain, and cerebral cortex tissues were collected by cold saline pressure expulsion and dissection.
For NaFl measurements, tissues were weighed, homogenized, extracted in 60% trichloroacetic acid, and centrifuged at 18,000 G for 20 minutes. A standard curve with NaFl (in 60% trichloroacetic acid) was generated and fluorescence intensity was measured in supernatants (in duplicate) using a spectrophotometer at an excitation wavelength of 420 nm and emission wavelength of 525 nm. For Evans Blue dye measurements, tissues were weighed and extracted in formamide for 72 hours at 65°C. Tissues were then centrifuged at 18,000G for 20 minutes. A standard curve with Evans Blue dye (in formamide) was generated and fluorescence intensity was measured in supernatants (in duplicate) using a spectrophotometer at a wavelength of 620 nm. All measurements were converted to dye concentration per tissue weight.
DNX carried out behavioral tests, tissue processing/immunostaining, data analysis, designed and coordinated experiments, and wrote the manuscript. IP carried out tissue processing/immunostaining and data analysis. GW carried out immunostaining and western blot, data analysis, and provided general technical support. JS conceptualized and directed the project. All authors read and approved the final manuscript.
We are grateful to Professors Hans Lassmann and Monika Bradl for kindly providing EAE animals used in pilot studies, help with histological analysis, and useful discussions. We would also like to thank Dr. Céline Heinl for technical assistance. This work was supported by a grant from the Austrian Science Fund (#P22306-B19) to J.S.
- Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M: The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol 2011, 70: 194–206. 10.1002/ana.22421View ArticlePubMed
- Choi YK, Kim K-W: Blood-neural barrier: its diversity and coordinated cell-to-cell communication. BMB Rep 2008, 41: 345–352. 10.5483/BMBRep.2008.41.5.345View ArticlePubMed
- de Vries HE, Kuiper J, de Boer AG, Van Berkel TJ, Breimer DD: The blood–brain barrier in neuroinflammatory diseases. Pharmacol Rev 1997, 49: 143–155.PubMed
- Sharma HS: Pathophysiology of blood-spinal cord barrier in traumatic injury and repair. Curr Pharm Design 2005, 11: 1353–1389. 10.2174/1381612053507837View Article
- Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, et al.: Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE 2007, 2: e1205-e1205. 10.1371/journal.pone.0001205PubMed CentralView ArticlePubMed
- Morgan L, Shah B, Rivers LE, Barden L, Groom AJ, Chung R, et al.: Inflammation and dephosphorylation of the tight junction protein occludin in an experimental model of multiple sclerosis. Neuroscience 2007, 147: 664–673. 10.1016/j.neuroscience.2007.04.051View ArticlePubMed
- Gordh T, Chu H, Sharma HS: Spinal nerve lesion alters blood-spinal cord barrier function and activates astrocytes in the rat. Pain 2006, 124: 211–221. 10.1016/j.pain.2006.05.020View ArticlePubMed
- Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ: Structure and function of the blood–brain barrier. Neurobiol Dis 2010, 37: 13–25. 10.1016/j.nbd.2009.07.030View ArticlePubMed
- Marchi N, Teng Q, Ghosh C, Fan Q, Nguyen MT, Desai NK, et al.: Blood–brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Res 2010, 1353: 176–186.PubMed CentralView ArticlePubMed
- Li Y-Q, Chen P, Haimovitz-Friedman A, Reilly RM, Wong CS: Endothelial apoptosis initiates acute blood–brain barrier disruption after ionizing radiation. Cancer Res 2003, 63: 5950–5956.PubMed
- Škultétyová I, Tokarev D, Ježová D: Stress-induced increase in blood–brain barrier permeability in control and monosodium glutamate-treated rats. Brain Res Bull 1998, 45: 175–178. 10.1016/S0361-9230(97)00335-3View ArticlePubMed
- Sharma HS, Ali SF: Acute administration of 3,4-methylenedioxymethamphetamine induces profound hyperthermia, blood–brain barrier disruption, brain edema formation, and cell injury. Ann N Y Acad Sci 2008, 1139: 242–258. 10.1196/annals.1432.052View ArticlePubMed
- Kiyatkin EA, Sharma HS: Permeability of the blood–brain barrier depends on brain temperature. Neuroscience 2009, 161: 926–939. 10.1016/j.neuroscience.2009.04.004PubMed CentralView ArticlePubMed
- Stokely ME, Orr EL: Acute effects of calvarial damage on dural mast cells, pial vascular permeability, and cerebral cortical histamine levels in rats and mice. J Neurotrauma 2008, 25: 52–61. 10.1089/neu.2007.0397View ArticlePubMed
- Strbian D, Karjalainen-Lindsberg M-L, Tatlisumak T, Lindsberg PJ: Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab 2006, 26: 605–612. 10.1038/sj.jcbfm.9600228View ArticlePubMed
- Sayed BA, Christy AL, Walker ME, Brown MA: Meningeal mast cells affect early T cell central nervous system infiltration and blood–brain barrier integrity through TNF: a role for neutrophil recruitment? J Immunol 2010, 184: 6891–6900. 10.4049/jimmunol.1000126View ArticlePubMed
- Gillardon F, Vogel J, Hein S, Zimmermann M, Uhlmann E: Inhibition of carrageenan-induced spinal c-Fos activation by systemically administered c-fos antisense oligodeoxynucleotides may be facilitated by local opening of the blood-spinal cord barrier. J Neurosci Res 1997, 47: 582–589. 10.1002/(SICI)1097-4547(19970315)47:6<582::AID-JNR3>3.0.CO;2-9View ArticlePubMed
- Lu P, Gonzales C, Chen Y, Adedoyin A, Hummel M, Kennedy JD, et al.: CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system. Life Sci 2009, 85: 450–456. 10.1016/j.lfs.2009.07.009View ArticlePubMed
- Echeverry S, Shi XQ, Rivest S, Zhang J: Peripheral nerve injury alters blood-spinal cord barrier functional and molecular integrity through a selective inflammatory pathway. J Neurosci 2011, 31: 10819–10828. 10.1523/JNEUROSCI.1642-11.2011View ArticlePubMed
- Beggs S, Liu XJ, Kwan C, Salter MW: Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood–brain barrier. Mol Pain 2010, 6: 74–79. 10.1186/1744-8069-6-74PubMed CentralView ArticlePubMed
- Sharma HS, Patnaik R, Sharma A, Muresanu DF: F108 Cerebrolysim attenuates blood-spinal cord barrier disruption,astrocytic activation and neuronal damage in the rat spinal following formalin nociception. Eur J Pain 2012, 5: 105.View Article
- Oztas B, Camurcu S, Kaya M: Influence of sex on the blood brain barrier permeability during bicuculline-induced seizures. Int J Neurosci 1992, 65: 131–139. 10.3109/00207459209003284View ArticlePubMed
- Bake S, Friedman JA, Sohrabji F: Reproductive age-related changes in the blood brain barrier: expression of IgG and tight junction proteins. Microvasc Res 2009, 78: 413–424. 10.1016/j.mvr.2009.06.009PubMed CentralView ArticlePubMed
- Sun D, Whitaker JN, Wilson DB: Regulatory T cells in experimental allergic encephalomyelitis. III. Comparison of disease resistance in Lewis and Fischer 344 rats. Eur J Immunol 1999, 29: 1101–1106. 10.1002/(SICI)1521-4141(199904)29:04<1101::AID-IMMU1101>3.0.CO;2-#View ArticlePubMed
- McCaffrey G, Seelbach MJ, Staatz WD, Nametz N, Quigley C, Campos CR, et al.: Occludin oligomeric assembly at tight junctions of the blood–brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem 2008, 106: 2395–2409. 10.1111/j.1471-4159.2008.05582.xPubMed CentralView ArticlePubMed
- Gordh T, Sharma HS: Chronic spinal nerve ligation induces microvascular permeability disturbances, astrocytic reaction, and structural changes in the rat spinal cord. Acta Neurochir Suppl 2006, 96: 335–340. 10.1007/3-211-30714-1_70View ArticlePubMed
- Kaya M, Gurses C, Kalayci R, Ekizoglu O, Ahishali B, Orhan N, et al.: Morphological and functional changes of blood–brain barrier in kindled rats with cortical dysplasia. Brain Res 2008, 1208: 181–191.View ArticlePubMed
- Miller DS: Regulation of P-glycoprotein and other ABC drug transporters at the blood–brain barrier. Trends Pharmacol Sci 2010, 31: 246–254. 10.1016/j.tips.2010.03.003PubMed CentralView ArticlePubMed
- Wilson EH, Weninger W, Hunter CA: Trafficking of immune cells in the central nervous system. J Clin Invest 2010, 120: 1368–1379. 10.1172/JCI41911PubMed CentralView ArticlePubMed
- Zehendner CM, Librizzi L, de Curtis M, Kuhlmann CR, Luhmann HJ: Caspase-3 contributes to ZO-1 and Cl-5 tight-junction disruption in rapid anoxic neurovascular unit damage. PLoS ONE 2011, 6: e16760. 10.1371/journal.pone.0016760PubMed CentralView ArticlePubMed
- Hirase T, Staddon JM, Saitou M, Ando-Akatsuka Y, Itoh M, Furuse M, et al.: Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 1997, 110: 1603–1613.PubMed
- Wong V, Gumbiner BM: A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier. J Cell Biol 1997, 136: 399–409. 10.1083/jcb.136.2.399PubMed CentralView ArticlePubMed
- Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, et al.: Blood–brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol 2010, 229: 180–191. 10.1016/j.jneuroim.2010.08.011View ArticlePubMed
- Zhao Y, Liu X, Yu A, Zhou Y, Liu B: Diabetes-related alteration of occludin expression in rat blood-spinal cord barrier. Cell Biochem Biophys 2010, 58: 141–145. 10.1007/s12013-010-9099-7View ArticlePubMed
- Huber JD, Hau VS, Borg L, Campos CR, Egleton RD, Davis TP: Blood–brain barrier tight junctions are altered during a 72-h exposure to l-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol 2002, 283: H1531-H1537.View ArticlePubMed
- Sakakibara A, Furuse M, Saitou M, Ando-Akatsuka Y, Tsukita S: Possible involvement of phosphorylation of occludin in tight junction formation. J Cell Biol 1997, 137: 1393–1401. 10.1083/jcb.137.6.1393PubMed CentralView ArticlePubMed
- Feldman GJ, Mullin JM, Ryan MP: Occludin: structure, function and regulation. Adv Drug Deliv Rev 2005, 57: 883–917. 10.1016/j.addr.2005.01.009View ArticlePubMed
- Ge S, Pachter JS: Isolation and culture of microvascular endothelial cells from murine spinal cord. J Neuroimmunol 2006, 177: 209–214. 10.1016/j.jneuroim.2006.05.012View ArticlePubMed
- Pan W, Banks WA, Kastin AJ: Permeability of the blood–brain and blood-spinal cord barriers to interferons. J Neuroimmunol 1997, 76: 105–111. 10.1016/S0165-5728(97)00034-9View ArticlePubMed
- Prockop LD, Naidu KA, Binard JE, Ransohoff J: Selective permeability of [3H]-D-mannitol and [14C]-carboxyl-inulin across the blood–brain barrier and blood-spinal cord barrier in the rabbit. J Spinal Cord Med 1995, 18: 221–226.PubMed
- Trojano M, Defazio G, Ricchiuti F, De Salvia R, Livrea P: Serum IgG to brain microvascular endothelial cells in multiple sclerosis. J Neurol Sci 1996, 143: 107–113. 10.1016/S0022-510X(96)00184-0View ArticlePubMed
- Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD: Impairment of the blood-nerve and blood–brain barriers in apolipoprotein e knockout mice. Exp Neurol 2001, 169: 13–22. 10.1006/exnr.2001.7631View ArticlePubMed
- McKenzie AL, Hall JJ, Aihara N, Fukuda K, Noble LJ: Immunolocalization of endothelin in the traumatized spinal cord: relationship to blood-spinal cord barrier breakdown. J Neurotrauma 1995, 12: 257–268. 10.1089/neu.1995.12.257View ArticlePubMed
- Nicaise C, Mitrecic D, Demetter P, De Decker R, Authelet M, Boom A, et al.: Impaired blood–brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res 2009, 1301: 152–162.View ArticlePubMed
- Nesic O, Lee J, Ye Z, Unabia GC, Rafati D, Hulsebosch CE, et al.: Acute and chronic changes in aquaporin 4 expression after spinal cord injury. Neuroscience 2006, 143: 779–792. 10.1016/j.neuroscience.2006.08.079PubMed CentralView ArticlePubMed
- Sandkühler J: Spinal plasticity and pain. In Wall and Melzack's Textbook of Pain. Edited by: Koltzenburg M, McMahon S. Elsevier, Churchill Livingstone; 2012. in the press
- Honda M, Nakagawa S, Hayashi K, Kitagawa N, Tsutsumi K, Nagata I, et al.: Adrenomedullin improves the blood–brain barrier function through the expression of claudin-5. Cell Mol Neurobiol 2006, 26: 109–118. 10.1007/s10571-006-9028-xView ArticlePubMed
- Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, et al.: Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 1998, 243: 816–820. 10.1006/bbrc.1997.8132View ArticlePubMed
- Sun H, Johnson DR, Finch RA, Sartorelli AC, Miller DW, Elmquist WF: Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun 2001, 284: 863–869. 10.1006/bbrc.2001.5062View ArticlePubMed
- Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD: Increased blood–brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 2007, 50: 202–211.View ArticlePubMed
- Hawkins BT, Ocheltree SM, Norwood KM, Egleton RD: Decreased blood–brain barrier permeability to fluorescein in streptozotocin-treated rats. Neurosci Lett 2007, 411: 1–5. 10.1016/j.neulet.2006.09.010PubMed CentralView ArticlePubMed
- Costello AH, Hargreaves KM: Suppression of carrageenan-induced hyperalgesia, hyperthermia and edema by a bradykinin antagonist. Eur J Pharmacol 1989, 171: 259–263. 10.1016/0014-2999(89)90118-0View ArticlePubMed
- Wolka AM, Huber JD, Davis TP: Pain and the blood–brain barrier: obstacles to drug delivery. Adv Drug Deliv Rev 2003, 55: 987–1006. 10.1016/S0169-409X(03)00100-5View ArticlePubMed
- Sharma HS, Kiyatkin EA: Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: an experimental study using light and electron microscopy. J Chem Neuroanat 2009, 37: 18–32. 10.1016/j.jchemneu.2008.08.002PubMed CentralView ArticlePubMed
- Kiyatkin EA, Brown PL, Sharma HS: Brain edema and breakdown of the blood–brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur J Neurosci 2007, 26: 1242–1253. 10.1111/j.1460-9568.2007.05741.xView ArticlePubMed
- Tall JM, Crisp T: Effects of gender and gonadal hormones on nociceptive responses to intraplantar carrageenan in the rat. Neurosci Lett 2004, 354: 239–241. 10.1016/j.neulet.2003.09.081View ArticlePubMed
- Greenspan JD, Craft RM, LeResche L, Arendt-Nielsen L, Berkley KJ, Fillingim RB, et al.: Studying sex and gender differences in pain and analgesia: a consensus report. Pain 2007, 132: S26-S45.PubMed CentralView ArticlePubMed
- Seker FB, Akgul S, Oztas B: Lifelong consumption of sodium selenite: gender differences on blood–brain barrier permeability in convulsive, hypoglycemic rats. Biol Trace Elem Res 2008, 124: 12–19. 10.1007/s12011-008-8101-3View ArticlePubMed
- Oztas B, Akgul S, Seker FB: Gender difference in the influence of antioxidants on the blood–brain barrier permeability during pentylenetetrazol-induced seizures in hyperthermic rat pups. Biol Trace Elem Res 2007, 118: 77–83. 10.1007/s12011-007-0020-1View ArticlePubMed
- Minami T, Sakita Y, Ichida S, Dohi Y: Gender difference regarding selenium penetration into the mouse brain. Biol Trace Elem Res 2002, 89: 85–93. 10.1385/BTER:89:1:85View ArticlePubMed
- Sirav B, Seyhan N: Effects of radiofrequency radiation exposure on blood–brain barrier permeability in male and female rats. Electromagn Biol Med 2011, 30: 253–260. 10.3109/15368378.2011.600167View ArticlePubMed
- Brooks TA, Nametz N, Charles R, Davis TP: Diclofenac attenuates the regional effect of lambda-carrageenan on blood–brain barrier function and cytoarchitecture. J Pharmacol Exp Ther 2008, 325: 665–673. 10.1124/jpet.107.135632View ArticlePubMed
- Campos CR, Ocheltree SM, Hom S, Egleton RD, Davis TP: Nociceptive inhibition prevents inflammatory pain induced changes in the blood–brain barrier. Brain Res 2008, 1221: 6–13.PubMed CentralView ArticlePubMed
- Bake S, Sohrabji F: 17b-estradiol differentially regulates blood–brain barrier permeability in young and aging female rats. Endocrinology 2004, 145: 5471–5475. 10.1210/en.2004-0984View ArticlePubMed
- Huber JD, Witt KA, Hom S, Egleton RD, Mark KS, Davis TP: Inflammatory pain alters blood–brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 2001, 280: H1241-H1248.PubMed
- Hawkins BT, Davis TP: The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57: 173–185. 10.1124/pr.57.2.4View ArticlePubMed
- Lisi L, Navarra P, Cirocchi R, Sharp A, Stigliano E, Feinstein DL, et al.: Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis. J Neuroimmunol 2012, 243: 43–51. 10.1016/j.jneuroim.2011.12.018View ArticlePubMed
- Lin T, Li K, Zhang F-Y, Zhang Z-K, Light AR, Fu K-Y: Dissociation of spinal microglia morphological activation and peripheral inflammation in inflammatory pain models. J Neuroimmunol 2007, 192: 40–48. 10.1016/j.jneuroim.2007.09.003PubMed CentralView ArticlePubMed
- Xanthos DN, Gaderer S, Drdla R, Nuro E, Abramova A, Ellmeier W, et al.: Central nervous system mast cells in peripheral inflammatory nociception. Mol Pain 2011, 7: 42–58. 10.1186/1744-8069-7-42PubMed CentralView ArticlePubMed
- Cahill CM, Dray A, Coderre TJ: Enhanced thermal antinociceptive potency and anti-allodynic effects of morphine following spinal administration of endotoxin. Brain Res 2003, 960: 209–218. 10.1016/S0006-8993(02)03885-4View ArticlePubMed
- Nicolussi EM, Huck S, Lassmann H, Bradl M: The cholinergic anti-inflammatory system limits T cell infiltration into the neurodegenerative CNS, but cannot counteract complex CNS inflammation. Neurobiol Dis 2009, 35: 24–31. 10.1016/j.nbd.2009.03.010View ArticlePubMed
- Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53: 55–63. 10.1016/0165-0270(94)90144-9View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.